Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

HBM Global Biotechnology Fund -USD-

Ranked 12 out of 12 in - Biotechnology over 12 months
All calculations are in CHF unless stated

Managed by

Ivo Staijen

HBM Partners' Ivo Staijen has over four years of experience in the pharma industry and over fourteen years of experience in investment analysis and portfolio management in the healthcare sector. He is also a former senior biotechnology analyst at Bank Sarasin and a former department head at MDS Pharma Services. Ivo has a Master of Science degree in chemistry from the University of Groningen, the Netherlands, and a PhD in biology from the Swiss Federal Institute of Technology (ETH), in Zurich, Switzerland. He also was a visiting scholar at the Department of Biology at the MIT, Cambridge, Massachusetts USA.

Objective

The fund's objective is to achieve long-term growth, which outperforms the reference index - NASDAQ Biotech Index in USD as far as possible. The fund invests mainly in shares of global firms, which operate in bio-technology and bio-pharmacy branches.

Showing fund performance in Switzerland View performance globally

Performance

Biotechnology over : 30/06/2016 - 30/06/2017

Total Return

Quarterly Performance

to 30/06/2017 Annual Q1 Q2 Q3 Q4
2017 9.7% 0.1%
2016 -19.1% -25.7% 2.7% 9.3% -3.0%
2015 17.8% 13.3% 3.9% -11.9% 13.7%
2014 60.9% 11.5% 8.2% 15.7% 15.4%
2013 56.8% 22.5% 4.5% 16.6% 5.1%
2012 24.8% 10.4% 9.7% 8.1% -4.7%

Month by Month Performance

Returns Vs Risk

Registered For Sale In

  1. Austria
  2. Germany
  3. Liechtenstein
  4. Switzerland

Fund Info

  • Launch date30/12/2011
  • Share Class size32Mn
  • Base currencyUSD
  • ISIN LI0130449403

Purchase Info

  • Min. initial investment1
  • Min. regular additional investment0

Charges

  • Annual management1.50%

Related News

Zug boutique brings biotech fund under Luxembourg umbrella

Firm moves fund from Liechtenstein to Luxembourg to reach wider client base.

Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated).